NeoClone produces high-quality monoclonal antibody products for the biotechnology and research markets. In addition to generating monoclonals through the traditional fusion technology NeoClone holds exclusive license to the ABL-MYC retroviral transformation system, a technique that produces monoclonal antibodies -- "NeoClone®"-brand or "NeoAb®" antibodies -- in an accelerated time and with cost savings. This allows NeoClone to provide custom antibodies faster and more cost effective.